Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018

Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018


  • Products Id :- GBIHC044IDB
  • |
  • Pages: 385
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pancreatic and Bile Duct Cancer Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for pancreatic and bile duct cancer. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pancreatic and bile duct cancer, and features dormant and discontinued products.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas, a large gland situated in the abdominal cavity that is responsible for the secretion of digestive fluids and insulin. Signs and symptoms include upper abdominal pain, yellowing of the skin and the whites of the eyes (jaundice), loss of appetite, weight loss, depression and blood clots.

Predisposing factors include age, gender, smoking, diabetes and family history. Treatments include surgery, chemotherapy and radiation therapy. There are 759 products in development for this indication.

Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile ducts, a series of tubes in the biliary tract that are essential for the secretion of bile, which plays an important role in digestion. Symptoms include discomfort in the abdomen, loss of appetite, fevers and weight loss. Treatment includes chemotherapy and radiation therapy. There are 133 products in development for this indication.

Molecular targets acted on by products in development for pancreatic and bile duct cancer include vascular endothelial growth factor receptors, programmed cell death protein 1 and signal transducer and activator of transcription 3. Companies operating in this pipeline space include Novartis, Eli Lilly and AstraZeneca.

Scope

- Which companies are the most active within the pipeline for pancreatic and bile duct cancer?

- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 13

2 Introduction 14

2.1 Pancreatic and Bile Duct Cancer Report Coverage 14

2.2 Pancreatic Cancer-Overview 14

2.3 Bile Duct Cancer (Cholangiocarcinoma)-Overview 14

3 Therapeutics Development 15

3.1 Pancreatic Cancer 15

3.2 Bile Duct Cancer (Cholangiocarcinoma) 67

4 Therapeutics Assessment 81

4.1 Pancreatic Cancer 81

4.2 Bile Duct Cancer (Cholangiocarcinoma) 113

5 Companies Involved in Therapeutics Development 125

5.1 Pancreatic Cancer 125

5.2 Bile Duct Cancer (Cholangiocarcinoma) 287

6 Dormant Projects 328

6.1 Pancreatic Cancer 328

6.2 Bile Duct Cancer (Cholangiocarcinoma) 344

7 Discontinued Products 347

7.1 Pancreatic Cancer 347

7.2 Bile Duct Cancer (Cholangiocarcinoma) 351

8 Product Development Milestones 352

8.1 Pancreatic Cancer 352

8.2 Bile Duct Cancer (Cholangiocarcinoma) 369

9 Appendix 384

9.1 Methodology 384

9.2 Coverage 384

9.3 Secondary Research 384

9.4 Primary Research 384

9.5 Expert Panel Validation 384

9.6 Contact Us 385

9.7 Disclaimer 385

1.2 List of Figures

Figure 1: Number of Products under Development for Pancreatic Cancer 15

Figure 2: Number of Products under Development by Companies, Pancreatic Cancer 16

Figure 3: Number of Products under Development by Universities/Institutes, Pancreatic Cancer 29

Figure 4: Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) 67

Figure 5: Number of Products under Development by Companies, Bile Duct Cancer (Cholangiocarcinoma) 68

Figure 6: Number of Products under Development by Universities/Institutes, Bile Duct Cancer (Cholangiocarcinoma) 72

Figure 7: Number of Products by Top 10 Targets, Pancreatic Cancer 81

Figure 8: Number of Products by Stage and Top 10 Targets, Pancreatic Cancer 81

Figure 9: Number of Products by Top 10 Mechanism of Actions, Pancreatic Cancer 93

Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions, Pancreatic Cancer 93

Figure 11: Number of Products by Top 10 Routes of Administration, Pancreatic Cancer 109

Figure 12: Number of Products by Stage and Top 10 Routes of Administration, Pancreatic Cancer 109

Figure 13: Number of Products by Top 10 Molecule Types, Pancreatic Cancer 111

Figure 14: Number of Products by Stage and Top 10 Molecule Types, Pancreatic Cancer 111

Figure 15: Number of Products by Top 10 Targets, Bile Duct Cancer (Cholangiocarcinoma) 113

Figure 16: Number of Products by Stage and Top 10 Targets, Bile Duct Cancer (Cholangiocarcinoma) 113

Figure 17: Number of Products by Top 10 Mechanism of Actions, Bile Duct Cancer (Cholangiocarcinoma) 117

Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions, Bile Duct Cancer (Cholangiocarcinoma) 117

Figure 19: Number of Products by Routes of Administration, Bile Duct Cancer (Cholangiocarcinoma) 121

Figure 20: Number of Products by Stage and Routes of Administration, Bile Duct Cancer (Cholangiocarcinoma) 121

Figure 21: Number of Products by Top 10 Molecule Types, Bile Duct Cancer (Cholangiocarcinoma) 123

Figure 22: Number of Products by Stage and Top 10 Molecule Types, Bile Duct Cancer (Cholangiocarcinoma) 123

1.1 List of Tables

Table 1: Number of Products under Development for Pancreatic Cancer 15

Table 2: Number of Products under Development by Companies, Pancreatic Cancer 17

Table 3: Number of Products under Development by Universities/Institutes, Pancreatic Cancer 30

Table 4: Products under Development by Companies, Pancreatic Cancer 32

Table 5: Products under Development by Universities/Institutes, Pancreatic Cancer 62

Table 6: Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) 67

Table 7: Number of Products under Development by Companies, Bile Duct Cancer (Cholangiocarcinoma) 69

Table 8: Number of Products under Development by Universities/Institutes, Bile Duct Cancer (Cholangiocarcinoma) 72

Table 9: Products under Development by Companies, Bile Duct Cancer (Cholangiocarcinoma) 73

Table 10: Products under Development by Universities/Institutes, Bile Duct Cancer (Cholangiocarcinoma) 80

Table 11: Number of Products by Stage and Target, Pancreatic Cancer 82

Table 12: Number of Products by Stage and Mechanism of Action, Pancreatic Cancer 94

Table 13: Number of Products by Stage and Route of Administration, Pancreatic Cancer 110

Table 14: Number of Products by Stage and Molecule Type, Pancreatic Cancer 112

Table 15: Number of Products by Stage and Target, Bile Duct Cancer (Cholangiocarcinoma) 114

Table 16: Number of Products by Stage and Mechanism of Action, Bile Duct Cancer (Cholangiocarcinoma) 118

Table 17: Number of Products by Stage and Route of Administration, Bile Duct Cancer (Cholangiocarcinoma) 122

Table 18: Number of Products by Stage and Molecule Type, Bile Duct Cancer (Cholangiocarcinoma) 124

Table 19: Pancreatic Cancer-Pipeline by 3-V Biosciences Inc 125

Table 20: Pancreatic Cancer-Pipeline by 4P-Pharma SAS 125

Table 21: Pancreatic Cancer-Pipeline by 4SC AG 126

Table 22: Pancreatic Cancer-Pipeline by AB Science SA 126

Table 23: Pancreatic Cancer-Pipeline by AbbVie Inc 127

Table 24: Pancreatic Cancer-Pipeline by AbGenomics International Inc 128

Table 25: Pancreatic Cancer-Pipeline by Ability Pharmaceuticals SL 128

Table 26: Pancreatic Cancer-Pipeline by Aclaris Therapeutics Inc 128

Table 27: Pancreatic Cancer-Pipeline by Actuate Therapeutics Inc 129

Table 28: Pancreatic Cancer-Pipeline by Adamed Sp z oo 129

Table 29: Pancreatic Cancer-Pipeline by Aduro BioTech Inc 130

Table 30: Pancreatic Cancer-Pipeline by Advantagene Inc 130

Table 31: Pancreatic Cancer-Pipeline by AGV Discovery SAS 131

Table 32: Pancreatic Cancer-Pipeline by AIMM Therapeutics BV 131

Table 33: Pancreatic Cancer-Pipeline by Alissa Pharma 132

Table 34: Pancreatic Cancer-Pipeline by Alligator Bioscience AB 132

Table 35: Pancreatic Cancer-Pipeline by Allinky Biopharma 132

Table 36: Pancreatic Cancer-Pipeline by Altor BioScience Corp 133

Table 37: Pancreatic Cancer-Pipeline by Ambrx Inc 133

Table 38: Pancreatic Cancer-Pipeline by amcure GmbH 134

Table 39: Pancreatic Cancer-Pipeline by Amgen Inc 134

Table 40: Pancreatic Cancer-Pipeline by Amplia Therapeutics Pty Ltd 135

Table 41: Pancreatic Cancer-Pipeline by Anavex Life Sciences Corp 135

Table 42: Pancreatic Cancer-Pipeline by Andarix Pharmaceuticals Inc 136

Table 43: Pancreatic Cancer-Pipeline by ANP Technologies Inc 136

Table 44: Pancreatic Cancer-Pipeline by AntiCancer Inc 136

Table 45: Pancreatic Cancer-Pipeline by APEIRON Biologics AG 137

Table 46: Pancreatic Cancer-Pipeline by Apexigen Inc 137

Table 47: Pancreatic Cancer-Pipeline by Aphios Corp 138

Table 48: Pancreatic Cancer-Pipeline by Aposense Ltd 138

Table 49: Pancreatic Cancer-Pipeline by ARMO Biosciences Inc 139

Table 50: Pancreatic Cancer-Pipeline by ArQule Inc 139

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

3-V Biosciences Inc

4P-Pharma SAS

4SC AG

AB Science SA

AbbVie Inc

AbGenomics International Inc

Ability Pharmaceuticals SL

Aclaris Therapeutics Inc

Actuate Therapeutics Inc

Adamed Sp z oo

Aduro BioTech Inc

Advantagene Inc

Advenchen Laboratories LLC

Agios Pharmaceuticals Inc

AGV Discovery SAS

AIMM Therapeutics BV

Alissa Pharma

Alligator Bioscience AB

Allinky Biopharma

Altor BioScience Corp

Ambrx Inc

amcure GmbH

Amgen Inc

Amplia Therapeutics Pty Ltd

Anavex Life Sciences Corp

Andarix Pharmaceuticals Inc

ANP Technologies Inc

AntiCancer Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

Aposense Ltd

Ariad Pharmaceuticals Inc

ARMO Biosciences Inc

ArQule Inc

Array BioPharma Inc

Asana BioSciences LLC

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

AVEO Pharmaceuticals Inc

Axcentua Pharmaceuticals AB

Basilea Pharmaceutica Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Berg LLC

BerGenBio ASA

Bexion Pharmaceuticals LLC

BeyondSpring Pharmaceuticals Inc

Bile Duct Cancer (Cholangiocarcinoma)

BioAtla LLC

BioLineRx Ltd

BioMoti Ltd

Biomunex Pharmaceuticals

Bionomics Ltd

BioNTech AG

Bio-Path Holdings Inc

Biothera Pharmaceutical Inc

Biouniversa srl

BLR Bio LLC

Boehringer Ingelheim GmbH

Boston Biomedical Inc

BriaCell Therapeutics Corp

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Cancer Prevention Pharmaceuticals Inc

Cantargia AB

Cantex Pharmaceuticals Inc

CARsgen Therapeutics Ltd

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cellular Biomedicine Group Inc

Celprogen Inc

Celyad SA

Centrose LLC

Chem-Master International Inc

ChemoCentryx Inc

Chugai Pharmaceutical Co Ltd

Clovis Oncology Inc

COARE Biotechnology Inc

Codiak BioSciences Inc

Concordia International Corp

Corcept Therapeutics Inc

Cotinga Pharmaceuticals Inc

CPL Biologicals Pvt Ltd

CrystalGenomics Inc

CTI BioPharma Corp

Cyclacel Pharmaceuticals Inc

CytImmune Sciences Inc

CytomX Therapeutics Inc

Cytori Therapeutics Inc

CyTuVax BV

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Debiopharm International SA

DEKK-TEC Inc

Delcath Systems Inc

Denceptor Therapeutics Ltd

Diffusion Pharmaceuticals Inc

Eddingpharm Inc

Eisai Co Ltd

Eleison Pharmaceuticals LLC

Eli Lilly and Co

Endor Nanotechnologies SL

Ensol Biosciences Inc

Enterome Bioscience SA

Erytech Pharma SA

Esperance Pharmaceuticals Inc

Etubics Corp

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Felicitex Therapeutics Inc

FibroGen Inc

Formation Biologics Inc

Formosa Laboratories Inc

Forty Seven Inc

Fountain Biopharma Inc

Fujifilm Holdings Corporation

Fusion Antibodies Ltd

Galera Therapeutics Inc

GamaMabs Pharma SA

Geistlich Pharma AG

Genelux Corp

Genentech Inc

Genisphere LLC

Genmab A/S

Genoscience Pharma

Gilead Sciences Inc

GlaxoSmithKline Plc

GlycoMimetics Inc

Glycotope GmbH

Golden Biotechnology Corp

GW Pharmaceuticals Plc

H3 Biomedicine Inc

Halozyme Therapeutics Inc

Heidelberg Pharma AG

Helix BioPharma Corp

Hemispherx Biopharma Inc

Horizon Pharma Plc

Hutchison MediPharma Ltd

Icell Kealex Therapeutics LLC

Idera Pharmaceuticals Inc

Igenica Biotherapeutics Inc

Ignyta Inc

Immix BioPharma Inc

Immodulon Therapeutics Ltd

Immune System Key Ltd

Immunitor Inc

Immunomedics Inc

Immunotope Inc

Immunovo BV

Immupharma Plc

Incyte Corp

Inflection Biosciences Ltd

Innopharmax Inc

Innovation Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

InteRNA Technologies BV

Intezyne Technologies Inc

Inventiva

InvivoGen Therapeutics

Io Therapeutics Inc

Iovance Biotherapeutics Inc

Ipsen SA

ISU ABXIS Co Ltd

Jasco Pharmaceuticals LLC

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Kalyra Pharmaceuticals Inc

Karcinolys SAS

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Keystone Nano Inc

Komipharm International Co Ltd

Kringle Pharma Inc

Kuhnil Pharmaceutical Co Ltd

Kura Oncology Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Leap Therapeutics Inc

Lexicon Pharmaceuticals Inc

LIfT BioSciences Ltd

Lixte Biotechnology Holdings Inc

Loxo Oncology Inc

Lymphocyte Activation Technologies SA

MabVax Therapeutics Holdings Inc

Machavert Pharmaceuticals LLC

MacroGenics Inc

MaxiVAX SA

Meabco AS

Mebiopharm Co Ltd

MediaPharma SRL

Medicenna Therapeutics Corp

MediciNova Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Merus NV

MetaMax Ltd

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Moderna Therapeutics Inc

Molecular Partners AG

Molecular Targeting Technologies Inc

Molecular Templates Inc

Moleculin Biotech LLC

Monopar Therapeutics Inc

Morphotek Inc

Mycenax Biotech Inc

NanoCarrier Co Ltd

NanoVector Inc

NantKwest Inc

Nascent Biotech Inc

Natco Pharma Ltd

NatureWise Biotech & Medicals Corp

NBE-Therapeutics AG

Nektar Therapeutics

Nerviano Medical Sciences Srl

NewLink Genetics Corp

NormOxys Inc

Northern Biologics Inc

Northwest Biotherapeutics Inc

Novartis AG

Noxxon Pharma AG

NuCana Plc

Oasmia Pharmaceutical AB

OBI Pharma Inc

Omeros Corp

Oncodesign SA

Oncology Research International Ltd

Oncolytics Biotech Inc

Oncomatryx Biopharma SL

OncoMed Pharmaceuticals Inc

OncoTherapy Science Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Optimum Therapeutics LLC

Oribase Pharma

Oryx GmbH & Co KG

OSE Immunotherapeutics

Oxford BioTherapeutics Ltd

Patrys Ltd

PCI Biotech Holding ASA

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

PharmaCyte Biotech Inc

Pharmedartis GmbH

Phenex Pharmaceuticals AG

Phoenix Biotechnology Inc

Plexxikon Inc

Polaris Pharmaceuticals Inc

POP Biotechnologies Inc

Precision Biologics Inc

Prescient Therapeutics Ltd

Propanc Biopharma Inc

Provecs Medical GmbH

Provectus Biopharmaceuticals Inc

Puma Biotechnology Inc

Purdue Pharma LP

Puretech Health plc

Quest PharmaTech Inc

Quimatryx SL

Rafael Pharmaceuticals Inc

RedHill Biopharma Ltd

Rexahn Pharmaceuticals Inc

Rhizen Pharmaceuticals SA

RS Research

Sagetis Biotech SL

Samumed LLC

Samyang Holdings Corp

Sanofi

Sareum Holdings Plc

SATT North SAS

Scancell Holdings Plc

Seattle Genetics Inc

Selecta Biosciences Inc

SELLAS Life Sciences Group Inc

Senhwa Biosciences Inc

Sensei Biotherapeutics Inc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Siamab Therapeutics Inc

Sichuan Kelun Pharmaceutical Co Ltd

Sierra Oncology Inc

SignalChem Lifesciences Corp

SignPath Pharma Inc

SilaGene Inc

Silenseed Ltd

Sillajen Biotherapeutics

Sino Biopharmaceutical Ltd

Sirnaomics Inc

Soricimed Biopharma Inc

Spring Bank Pharmaceuticals Inc

Strongbridge Biopharma plc

Sumitomo Dainippon Pharma Co Ltd

Sun BioPharma Inc

Sun Pharma Advanced Research Company Ltd

Swedish Orphan Biovitrum AB

Symic Biomedical Inc

Symphogen A/S

SynCore Biotechnology Co Ltd

Syndax Pharmaceuticals Inc

Synergys Biotherapeutics Inc

Synovo GmbH

SyntheX Inc

Taiho Pharmaceutical Co Ltd

Takara Bio Inc

Takeda Pharmaceutical Co Ltd

Takis Srl

Targovax ASA

Taris Biomedical LLC

Tarveda Therapeutics Inc

TCR2 Therapeutics Inc

tella Inc

Tesaro Inc

Tiziana Life Sciences Plc

Tocagen Inc

Transcriptogen Ltd

Transgene SA

Trovagene Inc

Tyg Oncology Ltd

Tyme Technologies Inc

Tyrogenex Inc

UbiVac LLC

ValiRx Plc

VasGene Therapeutics Inc

Vault Pharma Inc

Vaxeal Holding SA

Vaximm AG

Vaxon Biotech

VCN Biosciences SL

Vect-Horus SAS

Verastem Inc

VG Life Sciences Inc

Vicus Therapeutics LLC

Viralytics Ltd

Virobay Inc

ViroStatics srl

XBiotech Inc

XuanZhu Pharma Co Ltd

Zeria Pharmaceutical Co Ltd

select a license
Single User License
USD 3995 INR 289278
Site License
USD 7990 INR 578556
Corporate User License
USD 11985 INR 867834

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com